How PDHX Acetylation Affects Tumor Growth
Author Information
Author(s): Zetan Jiang, Nanchi Xiong, Ronghui Yan, Shi-ting Li, Haiying Liu, Qiankun Mao, Yuchen Sun, Shengqi Shen, Pinggen Zhang, Weidong Jia, Huafeng Zhang
Primary Institution: University of Science and Technology of China
Hypothesis
Does PDHX acetylation influence tumor progression by disrupting PDC assembly and activating lactylation-mediated gene expression?
Conclusion
PDHX acetylation at Lys 488 disrupts PDC assembly, leading to increased lactate production and promoting tumor progression.
Supporting Evidence
- PDHX acetylation at Lys 488 is significantly increased in HCC tissues compared to adjacent non-cancerous tissues.
- High levels of PDHX Lys 488 acetylation correlate with poor clinical prognosis in liver cancer patients.
- Knocking down PDHX leads to increased lactate production in cancer cells.
- PDHX Lys 488 acetylation inhibits the interaction between PDHX and DLAT, disrupting PDC assembly.
- Restoring PDHX function reduces lactate levels and H3K56 lactylation in cancer cells.
Takeaway
When a protein called PDHX gets a special tag (acetylation), it stops working properly, which helps cancer cells grow faster by changing how they use sugar.
Methodology
The study used mass spectrometry, immunoprecipitation, and RNA sequencing to analyze PDHX acetylation and its effects on PDC activity and gene expression.
Potential Biases
Potential bias in sample selection and the reliance on specific experimental models may affect the results.
Limitations
The study primarily focuses on PDHX in liver cancer, which may limit the generalizability of the findings to other cancer types.
Participant Demographics
The study involved human liver cancer tissues and cell lines.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website